NeuroSolv Therapeutics was set up to accelerate recovery from spinal cord injury by a high-achieving team of leading executives and clinicians through the development of a new drug therapy, Perineline™.

​

NeuroSolv Therapeutics successfully demonstrated the potential for significant improvement from Perineline™ to the European Medicines Agency which approved Perineline™ as an Orphan Designated drug therapy in March 2022. This provides regulatory acceleration for rare conditions across Europe, the USA, the UK, and Japan to facilitate swift market authorisation and access to treatments.

​

NeuroSolv Therapeutics is preparing to undertake a clinical trial of Perineline™ with some of the World’s leading spinal cord trauma hospitals in the USA.

​